Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07819799
PHASE1

Safety, Tolerability and PK of ATTO 1091 in Healthy Adult Volunteers and Patients With Ulcerative Colitis

Sponsor: Attovia Therapeutics Inc

View on ClinicalTrials.gov

Summary

The goal of this clinical trial is to assess the safety, tolerability, and pharmacokinetics (PK) of ATTO-1091 in healthy adults and patients with ulcerative colitis. The main questions it aims to answer are: What medical problems do participants have when taking ATTO-1091? How long does ATTO-1091 stay in the body after dosing? Researchers will compare ATTO-1091 to a placebo (a look-alike substance that contains no drug). Participants will be dosed with ATTO-1091 or a placebo, visit the clinic for checkups and tests, and keep a diary of their symptoms.

Official title: A Phase 1, Multi-Part, Single Ascending Dose and Multiple Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of ATTO 1091 in Healthy Adult Volunteers and Patients With Ulcerative Colitis

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

96

Start Date

2026-12-14

Completion Date

2028-07-15

Last Updated

2026-09-15

Healthy Volunteers

Yes

Interventions

DRUG

ATTO-1091

ATTO-1091

DRUG

Placebo

Placebo preparation to match ATTO-1091 dose